Press releases
- Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials
- ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS
- Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.
- Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program
- Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension
- Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis
- Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules
More ▼
Key statistics
On Friday, Endo International PLC (EO7:DEU) closed at 0.075, 650.00% above the 52 week low of 0.01 set on Sep 29, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.075 |
---|---|
High | 0.076 |
Low | 0.075 |
Bid | 0.075 |
Offer | 0.095 |
Previous close | 0.061 |
Average volume | 28.82k |
---|---|
Shares outstanding | 235.22m |
Free float | 233.36m |
P/E (TTM) | -- |
Market cap | 7.06m USD |
EPS (TTM) | -12.11 USD |
Data delayed at least 15 minutes, as of Jun 02 2023 20:51 BST.
More ▼